CMG Pharmaceutical Co., Ltd. (058820.KQ)
KRW 2600.0
(-0.95%)
KRW 2600.0
(-0.95%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 5.59 Billion KRW | 82.42% |
| 2022 | 5.26 Billion KRW | -3.92% |
| 2021 | 6.06 Billion KRW | 92.71% |
| 2020 | 3.02 Billion KRW | -22.65% |
| 2019 | 4.7 Billion KRW | 635.75% |
| 2018 | 4.41 Billion KRW | 23.81% |
| 2017 | 3.41 Billion KRW | 118.49% |
| 2016 | 2.6 Billion KRW | -77.42% |
| 2015 | -1.98 Billion KRW | 9.53% |
| 2014 | 1.9 Billion KRW | 30.33% |
| 2013 | 1.94 Billion KRW | 16.61% |
| 2012 | -2.84 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 3.89 Billion KRW | 52.75% |
| 2024 Q1 | 10.39 Billion KRW | 351.55% |
| 2023 Q2 | 4.99 Billion KRW | 49.62% |
| 2023 FY | - KRW | 82.42% |
| 2023 Q4 | -1.12 Billion KRW | -132.72% |
| 2023 Q1 | 3.33 Billion KRW | 171.5% |
| 2023 Q3 | 3.44 Billion KRW | -31.04% |
| 2022 Q3 | 414.03 Million KRW | 0.49% |
| 2022 FY | - USD | -3.92% |
| 2022 Q4 | -4.66 Billion KRW | -1227.68% |
| 2022 Q2 | 412.01 Million KRW | 54.78% |
| 2022 Q1 | 266.19 Million KRW | 16.11% |
| 2021 Q1 | 230.23 Million KRW | 20.47% |
| 2021 FY | - USD | 92.71% |
| 2021 Q2 | 311.87 Million KRW | 35.46% |
| 2021 Q3 | 307.52 Million KRW | -1.39% |
| 2021 Q4 | 229.25 Million KRW | -25.45% |
| 2020 Q3 | 175.26 Million KRW | 189.84% |
| 2020 Q1 | 138.83 Million KRW | -19.05% |
| 2020 Q2 | 60.47 Million KRW | -56.44% |
| 2020 FY | - USD | -22.65% |
| 2020 Q4 | 191.1 Million KRW | 9.04% |
| 2019 Q2 | 176.14 Million KRW | 3.08% |
| 2019 Q4 | 171.5 Million KRW | -1.3% |
| 2019 Q1 | 170.88 Million KRW | 46.59% |
| 2019 Q3 | 173.75 Million KRW | -1.36% |
| 2019 FY | - USD | 635.75% |
| 2018 FY | - USD | 23.81% |
| 2018 Q4 | 116.57 Million KRW | -12.31% |
| 2018 Q3 | 132.93 Million KRW | -16.89% |
| 2018 Q2 | 159.94 Million KRW | 10.63% |
| 2018 Q1 | 144.58 Million KRW | 37.96% |
| 2017 Q1 | 116.1 Million KRW | 64.78% |
| 2017 Q2 | 147.42 Million KRW | 26.98% |
| 2017 Q3 | 109.16 Million KRW | -25.95% |
| 2017 FY | - USD | 118.49% |
| 2017 Q4 | 104.8 Million KRW | -3.99% |
| 2016 FY | - USD | -77.42% |
| 2016 Q4 | 70.45 Million KRW | 10.44% |
| 2016 Q3 | 63.79 Million KRW | -20.41% |
| 2016 Q2 | 80.15 Million KRW | 934.96% |
| 2016 Q1 | -9.6 Million KRW | -106.7% |
| 2015 Q2 | 261.24 Million KRW | 12.29% |
| 2015 Q1 | 232.64 Million KRW | 5.83% |
| 2015 FY | - USD | 9.53% |
| 2015 Q4 | 143.2 Million KRW | -46.97% |
| 2015 Q3 | 270.06 Million KRW | 3.37% |
| 2014 Q4 | 219.83 Million KRW | -7.25% |
| 2014 Q3 | 237 Million KRW | 13.7% |
| 2014 Q2 | 208.45 Million KRW | 27.91% |
| 2014 Q1 | 162.96 Million KRW | 4.72% |
| 2014 FY | - USD | 30.33% |
| 2013 Q1 | 144.32 Million KRW | 15.24% |
| 2013 FY | - USD | 16.61% |
| 2013 Q3 | 164.17 Million KRW | -4.22% |
| 2013 Q2 | 171.41 Million KRW | 18.77% |
| 2013 Q4 | 155.61 Million KRW | -5.22% |
| 2012 Q4 | 125.23 Million KRW | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 581.09 Million KRW | -862.76% |
| Celltrion Pharm, Inc. | 54.22 Billion KRW | 89.683% |
| Huons Global Co., Ltd. | 151.92 Billion KRW | 96.318% |
| DongKook Pharmaceutical Co., Ltd. | 88.68 Billion KRW | 93.692% |
| Enzychem Lifesciences Corporation | -5.77 Billion KRW | 196.896% |
| Humedix Co., Ltd. | 54.87 Billion KRW | 89.805% |
| Boditech Med Inc. | 36.48 Billion KRW | 84.668% |
| EuBiologics Co., Ltd. | -4.39 Billion KRW | 227.385% |
| FutureChem Co.,Ltd | -591.25 Million KRW | 1046.207% |
| Huons Co., Ltd. | 74.23 Billion KRW | 92.464% |
| BNC Korea Co., Ltd. | 14.17 Billion KRW | 60.523% |
| AptaBio Therapeutics Inc. | -13 Billion KRW | 143.019% |